Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Asset Writedowns and Impairment (2017 - 2019)

Historic Asset Writedowns and Impairment for Mesa Laboratories (MLAB) over the last 3 years, with Q4 2019 value amounting to $276000.0.

  • Mesa Laboratories' Asset Writedowns and Impairment fell 9247.75% to $276000.0 in Q4 2019 from the same period last year, while for Mar 2020 it was $5.0 million, marking a year-over-year decrease of 7283.92%. This contributed to the annual value of $274.5 million for FY2024, which is N/A changed from last year.
  • Mesa Laboratories' Asset Writedowns and Impairment amounted to $276000.0 in Q4 2019, which was down 9247.75% from $1.1 million recorded in Q1 2019.
  • Over the past 5 years, Mesa Laboratories' Asset Writedowns and Impairment peaked at $13.8 million during Q4 2017, and registered a low of $276000.0 during Q4 2019.
  • In the last 3 years, Mesa Laboratories' Asset Writedowns and Impairment had a median value of $2.4 million in 2018 and averaged $4.7 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first tumbled by 7344.96% in 2018, then plummeted by 9247.75% in 2019.
  • Quarter analysis of 3 years shows Mesa Laboratories' Asset Writedowns and Impairment stood at $13.8 million in 2017, then tumbled by 73.45% to $3.7 million in 2018, then crashed by 92.48% to $276000.0 in 2019.
  • Its Asset Writedowns and Impairment stands at $276000.0 for Q4 2019, versus $1.1 million for Q1 2019 and $3.7 million for Q4 2018.